Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Prioritize Application Reviews for COVID-19 Products, Expecting Rush of Filings
June 21, 2021
- MHLW Aims to Set Up Evaluation Index, Sakigake System for SaMD by March
June 18, 2021
- Cymbalta Generics Priced at 33.2% of Originator Tags: June Listing
June 18, 2021
- 9 Drugs Face Generic Entries, AGx Debuts for 2 Brands: June Listing
June 17, 2021
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- Report Systems for Improper Drug Promotion Little-Known among Pharmacists: MHLW Study
June 16, 2021
- LDP Group Urges Stable Generic Supplies, Submits Proposal to MOF
June 16, 2021
- Label Revisions Ordered for New Safety Risks of Keytruda, Taltz
June 16, 2021
- Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
- MHLW Panel Recommends Lifting Ban on Cannabis-Derived Drugs, Eyes Legal Amendment Next Spring
June 15, 2021
- ICH Adopts Topic on Use of Real-World Data
June 15, 2021
- LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
- No Major Concerns over Safety of Moderna, Pfizer COVID-19 Vaccines: MHLW
June 11, 2021
- Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
- Japan PM Vows to Vaccinate All People by October-November
June 10, 2021
- LDP Panel Urges 500 Billion Yen Support over 10 Years for Japan-Made Jabs
June 9, 2021
- Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
- 33 New Products Including Celecoxib Added to 18th Edition of Japanese Pharmacopoeia
June 8, 2021
- G7 Health Ministers Adopt Declaration Aimed at Greater Cooperation to Expedite Drug, Vaccine Development
June 8, 2021
- Label Revision Ordered for Clozaril to Increase Blood Testing Interval, Relaxed Re-Administration Criteria
June 4, 2021
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…